Data from this trial found that higher response rates and longer PFS are significantly associated with higher T-cell-inflamed gene-expression profile (GEP), PD-L1 expression and tumor mutational burden (TMB; T-cell-inflamed GEP, P=0.012 and 0.017, n=203; PD-L1, P=0.018 and 0.005, n=198; TMB, P=0.018 and 0.051, n=77) (18). The gene discussed is CD274; the disease is neoplasm.